Who is sponsoring NCT07293325?

NCT07293325 is sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University.

What condition does NCT07293325 study?

NCT07293325 studies Adults With Simple Obesity.

What drugs are being tested in NCT07293325?

Interventions: Semaglutide, Tirzepatide, Metformin.

What is the status of NCT07293325?

NCT07293325 is currently RECRUITING.

Last reviewed 2025-12-19 · How we verify

Semaglutide and Tirzepatide for Genetic Aging Delay in Adults With Obesity

NCT07293325 NA RECRUITING

This study is a prospective, randomized, open-label clinical trial enrolling 66 adults with simple obesity who have not used weight-loss medications for at least 3 months. Participants will receive semaglutide, tirzepatide, or metformin for 24 weeks. Changes in "biological (epigenetic) age" will be assessed using the iWatchAge DNA methylation age test, while simultaneously monitoring improvements in aging-related biomarkers such as inflammatory factors, metabolic parameters, and body composition. The aim is to determine whether incretin-based therapies can reverse or slow obesity-related accelerated epigenetic aging and to provide new clinical evidence for interventions targeting obesity and aging.

Details

Lead sponsor	Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase	NA
Status	RECRUITING
Enrolment	66
Start date	Mon Jun 02 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Wed Jun 02 2027 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Adults With Simple Obesity

Interventions

Semaglutide
Tirzepatide
Metformin

Countries

China